Isabelle Staropoli

This study examines how SARS-CoV-2 RBD antibodies differ in function, showing that neutralizing antibodies lose effectiveness against variants but retain effector functions, while non-neutralizers remain broadly reactive but less effective overall.

This study shows human coronavirus HKU1 replicates more efficiently at nasal temperature (33°C) than at body temperature (37°C), with differences in innate immune response and viral stability.

This study shows TMPRSS2 reduces antibody binding to SARS-CoV-2 spike by altering its structure and shedding, but not virion infectivity.

This paper develops a single domain antibody targeting ACE2 that protects against SARS-CoV-2 infection in mice when delivered intranasally.

The paper evaluates the neutralization activity of two new monoclonal antibodies against emerging SARS-CoV-2 variants and finds reduced efficacy against some sublineages.

The paper develops a Lymphoid Organ-Chip to evaluate mRNA vaccine boosting strategies by mimicking immune responses to SARS-CoV-2 Spike protein and comparing monovalent and bivalent vaccines.

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

The paper identifies molecules that inhibit CCR5 transport to the cell surface and HIV infection by targeting palmitoylation.